CClinicalTrials.gg
CompletedNCT04457115Updated Nov 18, 2021

Erector Spinae Plane Block Versus Thoracic Paravertebral Block for Pain Control in Modified Radical Mastectomy

An interventional study of Thoracic paravertebral block and Erector spinae plane Block in Breast Surgery, Thoracic Paravertebral Block and Post-operative Pain Control, sponsored by AUSL Romagna Rimini. Completed at 1 site in Italy. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-11-18.

Sponsored by AUSL Romagna Rimini · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The aim of the study is to compare the effectiveness of the Erector spinae plane (ESP) block versus thoracic paravertebral (TPV) block in the post-operative pain control after radical mastectomy.

Read the detailed description

Primary outcome of our study is to compare the effectiveness of two regional anesthesia techniques, ESP block and TPV block, in the post-operative pain-control after radical mastectomy.

We will also evaluate both intra and post-operative opioid consumption, the incidence of PONV, the length of hospital stay, patient satisfaction with the anesthesiology technique and the incidence of chronic pain 6 months after surgery.

02

Conditions studied

  • Breast Surgery
  • Thoracic Paravertebral Block
  • Post-operative Pain Control
  • Erector Spinae Plane Block
  • Opioid Use

Browse trials for

Keywords

  • breast surgery
  • Thoracic paravertebral block
  • Erector spinae plane block
  • Mastectomy
  • post-operative pain control
03

In context

Pain, Postoperative

5,089 studies on the registry are indexed under Pain, Postoperative; 1,137 are open to participants now.

This study's enrollment of 78 is close to the median of 75 across 4,341 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

AUSL Romagna Rimini is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged between 18 and 85
  • American Society of Anesthesiologists classification I - III
  • Signature of consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Coagulopathies and / or use of antiplatelet / anticoagulant drugs
  • Infections and/or lesions at the puncture site,
  • BMI ≥40
  • allergies and / or contraindications to the administration of the drugs used in the study,
  • use of chronic opioid therapy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    TPV Block

    Thoracic paravertebral block performed at thoracic level T2-T3 and T4-T5 with administration of Ropivacaine 0.7% 8 ml for each level.

    Procedure: Thoracic paravertebral block

  • Experimental
    ESP Block

    Erector spinae plane block performed at thoracic level T2 and T5 with administration of Ropivacaine 0.5% 12 ml for each level.

    Procedure: Erector spinae plane Block

Interventions

  • ProcedureThoracic paravertebral block

    Thoracic paravertebral block performed at T2-T3 and T4-T5 levels with administration of Ropivacaine 0.7% 8 ml for each level

  • ProcedureErector spinae plane Block

    Erector spinae plane block performed at T2 and T5 levels with administration of Ropivacaine 0.5% 12 ml for each level

06

What researchers measure

Primary outcomes

  1. Post-operative pain assessment

    post-operative pain assessment using Numeric rating scale (from 0,no pain, to 10 ,worst pain)

    Time frame: 12 hours

Secondary outcomes

  1. Length of hospital stay

    The number of days of hospitalization after surgery will be assessed

    Time frame: 3 days

  2. Evaluate the incidence and severity of persistent pain 6 months after surgery

    Evaluate the incidence and severity of persistent pain 6 months after surgery using Numeric rating scale (from 0, no pain, to 10, worst pain)

    Time frame: six months

  3. Opioid use

    Intra and post-operative opioid use

    Time frame: 36 hours

  4. Incidence of PONV

    Incidence of post operative nausea and vomiting (PONV) in the first 36 hours

    Time frame: 36 hours

  5. Assessment of patient satisfaction with the anesthesiological technique

    Patients is requested to fill out a pre-printed sheet on their judgment of the anesthesiological procedure, in which they can express a value from 0 to 5, where 0 indicates "entirely dissatisfied" and 5 indi- cates "very satisfied"

    Time frame: 36 hours

07

Study locations

1 site
  • Domenico Pietro Santonastaso
    Cesena, Emilia Romagna 47521, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04457115
Lead sponsor
AUSL Romagna Rimini
Responsible party
Sponsor
First posted
Jul 7, 2020
Start date
Apr 27, 2020
Primary completion
Sep 30, 2021
Completion
Nov 15, 2021
Last update
Nov 18, 2021

Study contacts

Domenico P Santonastaso, MD
principal investigator · AUSL Romagna, M. Bufalini Hospital, Cesena

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion